Current status of the imaging diagnosis of liver fibrosis

Zheng You; Xu YongSheng; Zhang XuXia; Liu HaiFeng; Liu Zhao; Lei JunQiang

doi:10.3969/j.issn.1001-5256.2019.08.042

Volume 35 Issue 8

Aug. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(8): 1838-1841

PDF( 1933 KB)

Current status of the imaging diagnosis of liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2019.08.042

The First Clinical Medical College, Lanzhou University

Research funding:

Received Date: 2019-02-11
Published Date: 2019-08-20

Abstract

Abstract

Liver fibrosis is the result of the progressive development of various chronic liver diseases and can develop into liver cirrhosis and liver cancer with high mortality rates. Early diagnosis of liver fibrosis is of great significance for disease reversal. At present, liver biopsy is considered the gold standard for the diagnosis of liver fibrosis, but it cannot be used as a routine screening method due to its shortcomings.In recent years, progress has been made in various noninvasive imaging methods, and this article reviews the current status of the research on computed tomography, magnetic resonance imaging, nuclear medicine, and ultrasound in the diagnosis of liver fibrosis.
- liver cirrhosis,
- tomography, X-ray computed,
- magnetic resonance imaging,
- nuclear medicine,
- ultrasonography

FullText(HTML)

References(40)

References

[1] BEDOSSA P, POYNARD T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group[J]. Hepatology, 1996, 24 (2) :289-293.

[2] ISHAK K, BAPTISTA A, BIANCHI L, et al. Histological grading and staging of chronic hepatitis[J]. J Hepatol, 1995, 22 (6) :696-699.

[3] HUBER A, EBNER L, MONTANI M, et al. Computed tomography findings in liver fibrosis and cirrhosis[J]. Swiss Med Wkly, 2014, 144:w13923.

[4] OBMANN VC, MERTINEIT N, BERZIGOTTI A, et al. CT predicts liver fibrosis:Prospective evaluation of morphology-and attenuation-based quantitative scores in routine portal venous abdominal scans[J]. PLo S One, 2018, 13 (7) :e0199611.

[5] WANG L, FAN J, DING X, et al. Assessment of liver fibrosis in the early stages with perfusion CT[J]. Int J Clin Exp Med, 2015, 8 (9) :15276-15282.

[6] RONOT M, ASSELAH T, PARADIS V, et al. Liver fibrosis in chronic hepatitis C virus infection:Differentiating minimal from intermediate fibrosis with perfusion CT[J]. Radiology, 2010, 256 (1) :135-142.

[7] LI Y, PAN Q, ZHAO H. Investigation of the values of CT perfusion imaging and ultrasound elastography in the diagnosis of liver fibrosis[J]. Exp Ther Med, 2018, 16 (2) :896-900.

[8] SOFUE K, TSURUSAKI M, MILETO A, et al. Dual-energy computed tomography for non-invasive staging of liver fibrosis:Accuracy of iodine density measurements from contrastenhanced data[J]. Hepatol Res, 2018, 48 (12) :1008-1019.

[9] LAMB P, SAHANI DV, FUENTES-ORREGO JM, et al. Stratification of patients with liver fibrosis using dual-energy CT[J]. IEEE Trans Med Imaging, 2015, 34 (3) :807-815.

[10] LV P, LIN X, GAO J, et al. Spectral CT:Preliminary studies in the liver cirrhosis[J]. Korean J Radiol, 2012, 13 (4) :434-442.

[11] ZHAO LQ, HE W, YAN B, et al. The evaluation of haemodynamics in cirrhotic patients with spectral CT[J]. Br J Radiol, 2013, 86 (1028) :20130228.

[12] LIN ZR. GSI mode of spectral CT in diagnosis of liver fibrosis in experimental animals[D]. Shantou:Shantou University, 2013. (in Chinese) 林植荣.能谱CT GSI mode对肝纤维化诊断价值的实验动物研究[D].汕头:汕头大学, 2013.

[13] LIU HF, XU YS, ZHANG Y, et al. Value of magnetic resonance morphological imaging in the diagnosis and differentiation of post-hepatitis B cirrhosis[J]. J Clin Hepatol, 2018, 34 (12) :2587-2591. (in Chinese) 刘海峰, 许永生, 张跃, 等. MR形态学成像在乙型肝炎肝硬化诊断及分期中的应用价值[J].临床肝胆病杂志, 2018, 34 (12) :2587-2591.

[14] ZHOU JL, ZHANG ZG, HUANG JQ, et al. Modified hilar portal space measurement on MRI:Association with the stage of liver fibrosis and cirrhosis[J]. J Clin Radiol, 2018, 37 (1) :70-73. (in Chinese) 周家龙, 张振光, 黄建强, 等. MRI改良法测量门静脉右支前间隙改变与肝纤维化、肝硬化病理学分期的相关性研究[J].临床放射学杂志, 2018, 37 (1) :70-73.

[15] JIANG H, CHEN J, GAO R, et al. Liver fibrosis staging with diffusion-weighted imaging:A systematic review and metaanalysis[J]. Abdom Radiol (NY) , 2017, 42 (2) :490-501.

[16] KOCAKOC E, BAKAN AA, POYRAZOGLU OK, et al. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using different b-values in chronic viral hepatitis[J]. Med Princ Pract, 2015, 24 (6) :522-526.

[17] OZKURT H, KESKINER F, KARATAG O, et al. Diffusion weighted MRI for hepatic fibrosis:Impact of b-value[J]. Iran J Radiol, 2014, 11 (1) :e3555.

[18] CHEN C, FU F, ZHANG J, et al. Evaluation of liver fibrosis with a monoexponential model of intravoxel incoherent motion magnetic resonance imaging[J]. Oncotarget, 2018, 9 (37) :24619-24626.

[19] ZHANG B, LIANG L, DONG Y, et al. Intravoxel incoherent motion MR imaging for staging of hepatic fibrosis[J]. PLo S One, 2016, 11 (1) :e0147789.

[20] HAGIWARA M, RUSINEK H, LEE VS, et al. Advanced liver fibrosis:Diagnosis with 3D whole-liver perfusion MR imaging—initial experience[J]. Radiology, 2008, 246 (3) :926-934.

[21] SINGH S, VENKATESH SK, LOOMBA R, et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease:A diagnostic accuracy systematic review and individual participant data pooled analysis[J]. Eur Radiol, 2016, 26 (5) :1431-1440.

[22] WANG J, MALIK N, YIN M, et al. Magnetic resonance elastography is accurate in detecting advanced fibrosis in autoimmune hepatitis[J]. World J Gastroenterol, 2017, 23 (5) :859-868.

[23] HENNEDIGE TP, WANG G, LEUNG FP, et al. Magnetic resonance elastography and diffusion weighted imaging in the evaluation of hepatic fibrosis in chronic hepatitis B[J]. Gut Liver, 2017, 11 (3) :401-408.

[24] TANG CM, BANERJEE R, COLLIER J, et al. Liver fibrosis severity is associated with hepatic lipid composition as assessed by proton magnetic resonance spectroscopy[J]. Gut, 2016, 65 (1) :A92.

[25] PUUSTINEN L, HAKKARAINEN A, KIVISAARI R, et al.31Phosphorus magnetic resonance spectroscopy of the liver for evaluating inflammation and fibrosis in autoimmune hepatitis[J]. Scand J Gastroenterol, 2017, 52 (8) :886-892.

[26] GODFREY EM, PATTERSON AJ, PRIEST AN, et al. A comparison of MR elastography and31P MR spectroscopy with histological staging of liver fibrosis[J]. Eur Radiol, 2012, 22 (12) :2790-2797.

[27] YANG ZX, LIANG HY, HU XX, et al. Feasibility of histogram analysis of susceptibility-weighted MRI for staging of liver fibrosis[J]. Diagn Interv Radiol, 2016, 22 (4) :301-307.

[28] BALASSY C, FEIER D, PECK-RADOSAVLJEVIC M, et al. Susceptibility-weighted MR imaging in the grading of liver fibrosis:A feasibility study[J]. Radiology, 2014, 270 (1) :149-158.

[29] FUCHS BC, WANG H, YANG Y, et al. Molecular MRI of collagen to diagnose and stage liver fibrosis[J]. J Hepatol, 2013, 59 (5) :992-998.

[30] FARRAR CT, DEPERALTA DK, DAY H, et al. 3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model[J]. J Hepatol, 2015, 63 (3) :689-696.

[31] ZHU B, WEI L, ROTILE N, et al. Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model[J]. Hepatology, 2017, 65 (3) :1015-1025.

[32] HATORI A, YUI J, XIE L, et al. Utility of translocator protein (18 kDa) as a molecular imaging biomarker to monitor the progression of liver fibrosis[J]. Sci Rep, 2015, 5:17327.

[33] SCHNABL B, FARSHCHI-HEYDARI S, LOOMBA R, et al.Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models[J]. Nucl Med Biol, 2016, 43 (2) :179-187.

[34] TANIGUCHI M, OKIZAKI A, WATANABE K, et al. Hepatic clearance measured with (99m) Tc-GSA single-photon emission computed tomography to estimate liver fibrosis[J].World J Gastroenterol, 2014, 20 (44) :16714-16720.

[35] ZHANG D, ZHUANG R, GUO Z, et al. Desmin-and vimentin-mediated hepatic stellate cell-targeting radiotracer 99mTc-GlcNAc-PEI for liver fibrosis imaging with SPECT[J]. Theranostics, 2018, 8 (5) :1340-1349.

[36] SANGWAIYA MJ, SHERMAN DI, LOMAS DJ, et al. Latest developments in the imaging of fibrotic liver disease[J]. Acta Radiol, 2014, 55 (7) :802-813.

[37] LEI JW, TAN BB, LI WB, et al. Value of transient elastography measured with FibroTouch in the diagnosis of liver fibrosis in chronic hepatitis patients with hepatocellular carcinoma[J].Clin J Med Offic, 2017, 45 (9) :930-933. (in Chinese) 雷洁雯, 谭碧波, 李万斌, 等. FibroTouch瞬时弹性成像诊断慢性乙型肝炎合并肝癌患者肝纤维化程度应用研究[J].临床军医杂志, 2017, 45 (9) :930-933.

[38] LIU BR, DONG X, HUANG LP. Diagnostic efficacy of shear wave elastography in evaluating chronic hepatitis B liver fibrosis and related influencing factors[J]. J Clin Hepatol, 2018, 34 (11) :2329-2333. (in Chinese) 刘博儒, 董雪, 黄丽萍.剪切波弹性成像评估慢性乙型肝炎肝纤维化的价值及影响因素[J].临床肝胆病杂志, 2018, 34 (11) :2329-2333.

[39] LEUNG VY, SHEN J, WONG VW, et al. Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers:Comparison of shear-wave elastography and transient elastography with liver biopsy correlation[J]. Radiology, 2013, 269 (3) :910-918.

[40] ISHIBASHI H, MARUYAMA H, TAKAHASHI M, et al. Assessment of hepatic fibrosis by analysis of the dynamic behaviour of microbubbles during contrast ultrasonography[J]. Liver Int, 2010, 30 (9) :1355-1363.

Relative Articles

[1]	Ying TU, Xue LI, Meijuan CHEN, Huaqian XU, Shanhong TANG. Value of platelet count and related scoring models in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(6): 1308-1312. doi: 10.3969/j.issn.1001-5256.2023.06.009
[2]	Lu WANG, Wenxiong XU, Shu ZHU, Xuejun LI, Yuanli CHEN, Chan XIE, Liang PENG. Influence of artificial liver support system therapy on platelet in treatment of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(5): 1053-1058. doi: 10.3969/j.issn.1001-5256.2022.05.015
[3]	Xiao YU, Guobing WU, Aibin ZHANG, Xiaolong CHENG, Min LIU, Zenan HU, Ya ZHENG, Yuping WANG, Zhaofeng CHEN. Role of platelets in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(6): 1426-1430. doi: 10.3969/j.issn.1001-5256.2022.06.043
[4]	Wang ZhiXin, Li Yao, Zhou LiuXin, Ren Li, Qu Kai, Miao Run, Hou LiChao, Wang HaiJiu, Liu Chang, Fan HaiNing. Influence of 5-hydroxytryptamine and platelet count in peripheral blood on the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1534-1539. doi: 10.3969/j.issn.1001-5256.2020.07.017
[5]	Huang ChunMing, Yang Zhan, Nie YuQiang, Hu ZhongWei, Zhou YongJian, Zhan YuanJing, Guo JiaWei, Yu WeiHua. Value of FibroScan combined with gamma-glutamyl transpeptidase-to-platelet ratio in predicting liver fibrosis in patients with chronic hepatitis B:A preliminary study[J]. Journal of Clinical Hepatology, 2019, 35(2): 334-337. doi: 10.3969/j.issn.1001-5256.2019.02.018
[6]	Huang ChunMing, Yang Zhan, Nie YuQiang, Hu ZhongWei, Zhou YongJian, Zhan YuanJing, Guo JiaWei, Yu WeiHua. Value of gamma-glutamyl transpeptidase-to-platelet ratio in predicting liver fibrosis stage in chronic hepatitis B patients in Guangdong, China[J]. Journal of Clinical Hepatology, 2018, 34(6): 1204-1208. doi: 10.3969/j.issn.1001-5256.2018.06.015
[7]	Li PingYing, Yang YongGeng, Lu LunGen, Zhu ZhiYong, Wang YaPing, Ma YingCai. Value of microRNAs in diagnosis of chronic hepatitis B-related liver fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(12): 2412-2415. doi: 10.3969/j.issn.1001-5256.2017.12.036
[8]	Lin Yan, Li Xun. Research advances in the role of platelets in liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(11): 2243-2246. doi: 10.3969/j.issn.1001-5256.2017.11.043
[9]	Chen Nian, Huang WeiE, Su MingHua, Jiang JianNing. Correlation between platelet indices and liver pathological staging: an analysis of 167 patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(1): 106-109. doi: 10.3969/j.issn.1001-5256.2016.01.019
[10]	Li Qiang, Huang YuXian, Chen Liang. Simple serum markers for significant liver inflammation in chronic hepatitis B patients with an alanine aminotransferase level lower than 2 times upper limit of normal[J]. Journal of Clinical Hepatology, 2016, 32(6): 1125-1129. doi: 10.3969/j.issn.1001-5256.2016.06.021
[11]	Zheng JunFu, Cai ZhaoHua, Zhang Xin, Lou JinLi, Zhao WenMin, Li Peng, Li Bing, Li Lei, Dong PeiLing, Ding HuiGuo. Value of single or combined measurement of serum PCT,peripheral WBC,and WBC/PCT for early diagnosis of bacterial infection in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 209-213. doi: 10.3969/j.issn.1001-5256.2015.02.016
[12]	Gao Chun, Fang Long, Yao ShuKun. Correlation of GGT with AFP and diagnostic value of GGT for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(9): 921-925. doi: 10.3969/j.issn.1001-5256.2014.09.021
[13]	Zhu Chen, Sun YuanYuan, Jin Yan. Values of serum AFP, GGTⅡ and GP73 in diagnosis of primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1064-1066. doi: 10.3969/j.issn.1001-5256.2014.10.022
[14]	Ding ShengNan, Yang WeiMin, Niu JunQi. Changes in platelet parameters and their influential factors in cirrhotic patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(6): 556-559. doi: 10.3969/j.issn.1001-5256.2014.06.020
[15]	Jin GuoHua, Po YunFeng, Chen ZhaoJie. Comparison on hematoblastic relevant parameter from patients with liver cirrhosis after heptitis B and patients with alcoholic cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(2): 102-104.

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	张玉婷，施欢，李虤，沈波. FibroTouch联合GGT/PLT比值对诊断乙型肝炎肝纤维化的临床价值. 江西医药. 2022(02): 206-209+216 .
2.	杜乔慧，吴克俭，王争争. GP73、GPR对慢性乙型肝炎患者肝硬化的诊断价值. 胃肠病学和肝病学杂志. 2022(07): 758-763 .
3.	鲁荣华. 血清IL-2和IL-10对重度慢性乙型肝炎患者糖皮质激素治疗预后的评估价值. 中国卫生工程学. 2020(01): 83-85 .
4.	毛桂芸，张永飞，郭延生，陶金忠. 山楂对围产期奶牛肝功能和血脂的影响. 中国奶牛. 2020(08): 36-39 .
5.	陈晓玲，宋倩. 剪切波弹性成像和γ-谷氨酰转肽酶/血小板比用于诊断慢性乙型肝炎患者肝纤维化. 中国医学影像技术. 2020(10): 1499-1503 .
6.	黄春明，杨湛，聂玉强，胡中伟，周永健，詹远京，郭家伟，余卫华. FibroScan联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化的初步探讨. 临床肝胆病杂志. 2019(02): 334-337 . 本站查看
7.	张小磊. 血清ALT、AST、GGT、HBV-DNA联合检测在慢性乙型肝炎病情评估中的应用. 内蒙古医学杂志. 2019(02): 211-212 .
8.	尹国云. 瞬时弹性超声检测对蒙古族地区慢性乙型病毒性肝炎患者抗病毒治疗临床指导意义的研究. 世界复合医学. 2019(06): 90-92+114 .
9.	黄春明，胡中伟，聂玉强，周永健，詹远京，郭家伟，余卫华. 无创诊断模式预测慢性乙型肝炎合并非酒精性脂肪肝患者肝纤维化的价值. 胃肠病学和肝病学杂志. 2019(08): 915-918 .
10.	黄春明，杨湛，聂玉强，胡中伟，周永健，詹远京，郭家伟，余卫华. GGT/PLT比值对广东地区慢性乙型肝炎患者肝纤维化分期的预测价值. 临床肝胆病杂志. 2018(06): 1204-1208 . 本站查看
11.	李曼，李涛，刘振杰，曹永坚，钟伟国，余婷玉，何敏，徐宁. 以血清学指标比值为变量的肝纤维化诊断模型构建与评价. 山东医药. 2018(18): 17-20 .
12.	李曼，张军，李涛，罗强，钟伟国，李嘉胜，徐宁. ADA/PLT、ALP/PLT比值对肝纤维化的诊断价值. 中国实验诊断学. 2017(11): 1923-1926 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1104) PDF downloads(244)

Current status of the imaging diagnosis of liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2019.08.042